{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:10:22Z","timestamp":1760782222278,"version":"3.41.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2002,1,1]],"date-time":"2002-01-01T00:00:00Z","timestamp":1009843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2002,1,1]],"date-time":"2002-01-01T00:00:00Z","timestamp":1009843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2002,1]]},"DOI":"10.1023\/a:1013850107791","type":"journal-article","created":{"date-parts":[[2002,12,28]],"date-time":"2002-12-28T18:50:27Z","timestamp":1041101427000},"page":"149-159","source":"Crossref","is-referenced-by-count":28,"title":["In Vitro Cytotoxicity of Bismuth-213 (213bi)-Labeled-Plasminogen Activator Inhibitor Type 2 (Alpha-PAI-2) on Human Breast Cancer Cells"],"prefix":"10.1007","volume":"71","author":[{"given":"M.","family":"Ranson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z.","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.M.","family":"Andronicos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Rizvi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.J.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"389578_CR1","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/00006231-199903000-00001","volume":"20","author":"BJ Allen","year":"1999","unstructured":"Allen BJ: Can alpha immunotherapy succeed where other systemic therapies have failed? Nucl Med Commun 20: 205\u2013207, 1999","journal-title":"Nucl Med Commun"},{"key":"389578_CR2","unstructured":"American Cancer Society (ACS): News Today of Breast Cancer Resource Center, June 28, 2000"},{"key":"389578_CR3","first-page":"227","volume":"1","author":"V Raso","year":"1990","unstructured":"Raso V: The magic bullet-nearing the century mark. Semin Cancer Biol 1: 227\u2013243, 1990","journal-title":"The magic bullet-nearing the century mark. Semin Cancer Biol"},{"key":"389578_CR4","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1046\/j.1440-1673.1999.00717.x","volume":"43","author":"BJ Allen","year":"1999","unstructured":"Allen BJ: Targeted alpha therapy: evidence for efficacy of alpha-immunoconjugates in the management of micrometastatic cancer. Australas Radiol 43: 480\u2013486, 1999","journal-title":"Australas Radiol"},{"key":"389578_CR5","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/00006231-199601000-00008","volume":"17","author":"BJ Allen","year":"1996","unstructured":"Allen BJ, Blagojevic N: Alpha and beta emitting radio lanthanides in targeted cancer therapy. Nucl Med Commun 17: 40\u201347, 1996","journal-title":"Nucl Med Commun"},{"key":"389578_CR6","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/0360-3016(87)90176-3","volume":"13","author":"JL Humm","year":"1987","unstructured":"Humm JL: A microdosimetric model of astatine-211 labeled antibodies for radioimmunotherapy. Int J Radiat Oncol Biol Phys 13: 1767\u20131773, 1987","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"389578_CR7","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/0360-3016(84)90052-X","volume":"10","author":"WD Bloomer","year":"1984","unstructured":"Bloomer WD, McLaughlin WH, Lambrecht RM, Mirzadeh S, Madara JL, Milius RA, Zalutsky MR, Adelstein SJ, Wolf AP: 211At radiocolloid therapy: further observations and comparision with radiocolloids of 32P, 165Dy and 90Y. Int J Radiat Oncol Biol Phys 10:341, 1984","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"389578_CR8","first-page":"711","volume":"2","author":"RM Macklis","year":"1993","unstructured":"Macklis RM, Beresford BA, Palayoor S, Sweeney S, Humm JL: Cell cycle alterations, apoptosis, and response to low-doserate radioimmunotherapy in lymphoma cells. Int J Oncol 2: 711\u2013715, 1993","journal-title":"Int J Oncol"},{"key":"389578_CR9","first-page":"1944","volume":"38","author":"E Horak","year":"1997","unstructured":"Horak E, Hartmann F, Garmestani K, Wu C, Brechbiel M, Gansow OA, Landolfi NF, Waldmann TA: Radioimmunotherapy targeting of HER2\/neu oncoprotein on ovarian tumour using lead-212-DOTA-AE1. Nucl Med 38: 1944\u20131950, 1997","journal-title":"Nucl Med"},{"key":"389578_CR10","doi-asserted-by":"crossref","first-page":"152","DOI":"10.2307\/3579925","volume":"149","author":"RH Larsen","year":"1998","unstructured":"Larsen RH, Akabani G, Welsh P, Zalutski MR: The cytotoxicity and microdosimetry of astatine-211-labeled chimeric monoclonal antibodies in human glioma and melanoma cells in vitro. Radiat Res 149: 152\u2013157, 1998","journal-title":"Radiat Res"},{"key":"389578_CR11","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s002590050306","volume":"25","author":"MR McDevitt","year":"1998","unstructured":"McDevitt MR, Sgouros G, Finn RD, Humm JL, Jurcic JG, Larson SM, Scheinberg DA: Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med 25: 1341\u20131351, 1998","journal-title":"Eur J Nucl Med"},{"key":"389578_CR12","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0969-8043(98)00151-1","volume":"50","author":"MR McDevitt","year":"1998","unstructured":"McDevitt MR, Finn RD, Sgouros G, Ma D, Scheinberg DA: An 225Ac\/213Bi generator system for therapeutic clinical applications: construction and operation. Appl Rad Isot 50: 895\u2013904, 1998","journal-title":"Appl Rad Isot"},{"key":"389578_CR13","unstructured":"Van Geel JNC, Fuger J, Koch L: Verfahern zur erzeugung von actinium-225 und Bismuth-213 European Patent no. 0 443 479 B1. 1994"},{"key":"389578_CR14","first-page":"341","volume":"40","author":"RA Boll","year":"1998","unstructured":"Boll RA, Mirzadeh S, Kennel SJ, DePaoli DW, Webb OF: 213Bi for alpha-particle-mediated radioimmunotherapy. J Label Compds Radiopharm 40: 341, 1998","journal-title":"J Label Compds Radiopharm"},{"key":"389578_CR15","first-page":"166","volume":"40","author":"TK Nikula","year":"1999","unstructured":"Nikula TK, McDevitt MR, Finn RD: Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry. J Nucl Med 40: 166\u2013176, 1999","journal-title":"J Nucl Med"},{"key":"389578_CR16","doi-asserted-by":"crossref","first-page":"244","DOI":"10.2307\/3579935","volume":"151","author":"SJ Kennel","year":"1999","unstructured":"Kennel SJ, Stabin M, Roeske JC, Foote LJ, Lankford PK, Terzaghi-Howe M, Patterson H, Barkenbus J, Popp DM, Boll R, Mirzadeh S: Radiotoxicity of bismuth-213 bound to membranes of monolayer and spheroid cultures of tumor cells. Radiat Res 151: 244\u2013256, 1999","journal-title":"Radiat Res"},{"key":"389578_CR17","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/sj.bjc.6690337","volume":"80","author":"SJ Kennel","year":"1999","unstructured":"Kennel SJ, Boll R, Stabin M, Schuller HM, Mirzadeh S: Radioimmunotherapy of micrometastases in lung with vascular targeted 213Bi. Br J Cancer 80: 175\u2013184, 1999","journal-title":"Br J Cancer"},{"key":"389578_CR18","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/00008390-200010030-00011","volume":"10","author":"SM Rizvi","year":"2000","unstructured":"Rizvi SM, Sarkar S, Goozee G, Allen BJ: Radioimmunoconjugates for targeted alpha therapy of malignant melanoma. Melanoma Res 10: 281\u2013290, 2000","journal-title":"Melanoma Res"},{"key":"389578_CR19","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0969-8051(00)00103-7","volume":"27","author":"GP Adams","year":"2000","unstructured":"Adams GP, Shaller CC, Chappell LL, Wu C, Horak M, Simmons HH, Litwin S, Marks JD, Weiner LMN, Brechbiel MW: Delivery of the alpha-emitting radioisotope bismuth-213 to solid tumours by a single-chain Fv and diabody molecules. Nucl Med Biol 27: 339\u2013346, 2000","journal-title":"Nucl Med Biol"},{"key":"389578_CR20","first-page":"6095","volume":"60","author":"MR McDevitt","year":"2000","unstructured":"McDevitt MR, Barendswaard E, Ma D: An alpha-particle emmitting antibody (213Bi-J591) for radioimmunotherapy of prostate cancer. Cancer Res 60: 6095\u20136100, 2000","journal-title":"Cancer Res"},{"key":"389578_CR21","unstructured":"Rizvi SMR, Allen BJ, Tian Z, Sarkar S.: In vitro and preclinical studies of targeted alpha therapy for colorectal cancer. Colorectal Disease (in press)."},{"key":"389578_CR22","unstructured":"Rizvi SMR, Henniker AJ, Goozee G, Allen BJ: In vitro testing of the leukaemia monoclonal antibody WM-53 labeled with alpha and beta emitting radioisotopes. Leukaemia Res (in press)"},{"key":"389578_CR23","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0065-230X(08)61002-7","volume":"57","author":"J Pollanen","year":"1991","unstructured":"Pollanen J, Stephens R, Vaheri A: Directed plasminogen activation at the surface of normal and malignant cells. Adv Cancer Res 57: 273\u2013328, 1991","journal-title":"Adv Cancer Res"},{"key":"389578_CR24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z","volume":"72","author":"PA Andreasen","year":"1997","unstructured":"Andreasen PA, Kjoller L, Christensen L, Duffy M. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72: 1\u201322, 1997","journal-title":"Int J Cancer"},{"key":"389578_CR25","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1054\/fipr.2000.0079","volume":"14","author":"M Schmitt","year":"2000","unstructured":"Schmitt M, Wilhelm OG, Reuning U: The urokinase plasminogen activation system as a novel target for tumour therapy. Fibrinol Proteol 14: 114\u2013132, 2000","journal-title":"Fibrinol Proteol"},{"key":"389578_CR26","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1515\/bchm3.1992.373.2.611","volume":"373","author":"M Schmitt","year":"1992","unstructured":"Schmitt M, Janicke F, Chucholowski N, Pache L, Graeff H: Tumour-associated urokinase-type plasminogen activator: biological and clinical significance. Biol Chem Hoppe-Seyler 373: 611\u2013622, 1992","journal-title":"Biol Chem Hoppe-Seyler"},{"key":"389578_CR27","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/BF01052889","volume":"22","author":"M Yamamoto","year":"1994","unstructured":"Yamamoto M, Sawaya R, Mohanam S: Activities, localizations, and roles of serine proteases and their inhibitors in human brain tumour progression. J Neuro Oncol 22: 139\u2013151, 1994","journal-title":"J Neuro Oncol"},{"key":"389578_CR28","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1699-0463.1999.tb01537.x","volume":"107","author":"S Mustojoki","year":"1999","unstructured":"Mustojoki S, Alitalo R, Stephens RW, Vaheri A: Plasminogen activation in human leukemia and in normal hematopoietic cells. APMIS 107: 144\u2013149, 1999","journal-title":"APMIS"},{"key":"389578_CR29","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0002-9440(10)64637-8","volume":"157","author":"E Dublin","year":"2000","unstructured":"Dublin E, Hanby A, Patel NK, Liebman R, Barnes D: Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma \u2013 fibroblastic expression has strong associations with tumour pathology. Am J Pathol 157: 1219\u20131227, 2000","journal-title":"Am J Pathol"},{"key":"389578_CR30","first-page":"861","volume":"54","author":"E Bianchi","year":"1994","unstructured":"Bianchi E, Cohen RL, Thor AT, Todd RF III, Mizukami IF, Lawrence DA, Ljung BM, Shuman MA, Smith HS: The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. Cancer Res 54: 861\u2013866, 1994","journal-title":"Cancer Res"},{"key":"389578_CR31","first-page":"3198","volume":"53","author":"S Del Vecchio","year":"1993","unstructured":"Del Vecchio S, Stoppelli MP, Carriero MV: Human urokinase receptor concnetratin in malignant and benign breast tumours by in vitro quantitative autoradiography: comparison with urokinase levels. Cancer Res 53: 3198\u20133206, 1993","journal-title":"Cancer Res"},{"key":"389578_CR32","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/(SICI)1097-0215(19960516)66:4<441::AID-IJC6>3.0.CO;2-W","volume":"66","author":"L Christensen","year":"1996","unstructured":"Christensen L, Wiborg Simonsen AC, Heegaard CW: Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and a2-macroglobulin receptor in human breast carcinomas. Int J Cancer 66: 441\u2013452, 1996","journal-title":"Int J Cancer"},{"key":"389578_CR33","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1002\/(SICI)1097-0142(19960315)77:6<1079::AID-CNCR12>3.0.CO;2-Z","volume":"77","author":"V Constantini","year":"1996","unstructured":"Constantini V, Sidoni A, Deveglia R: Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression. Cancer 77: 1079\u20131088, 1996","journal-title":"Cancer"},{"key":"389578_CR34","first-page":"1","volume":"61","author":"JL Fisher","year":"2000","unstructured":"Fisher JL, Field CL, Zhou H: Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases \u2013 a comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases. Br Cancer Res Treat 61: 1\u201312, 2000","journal-title":"Br Cancer Res Treat"},{"key":"389578_CR35","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1182\/blood.V86.11.4007.bloodjournal86114007","volume":"86","author":"EKO Kruith","year":"1995","unstructured":"Kruith EKO, Baker MS, Bunn CL: Biochemistry, cellular and molecular biology and clinical aspects of plasminogen activator inhibitor type-2. Blood 86: 4007\u20134024, 1995","journal-title":"Blood"},{"key":"389578_CR36","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0268-9499(98)80296-8","volume":"12","author":"MTN Hang","year":"1998","unstructured":"Hang MTN, Ranson M, Saunders DN, Liang XM, Bunn CL, Baker MS: Pharmacokinetics and biodistribution of recombinant human plasminogen activator inhibitor type 2 (PAI-2) in control and tumour xenograft-bearing mice. Fibrinol Proteol12: 145\u2013154, 1998","journal-title":"Fibrinol Proteol"},{"key":"389578_CR37","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0167-4838(96)00146-X","volume":"1337","author":"NM Andronicos","year":"1997","unstructured":"Andronicos NM, Ranson M, Bognacki J, Baker MS: The human ENO1 gene product (recombinant human alpha-enolase) displays characteristics required for a plasminogen binding protein. Biochimica et Biophysica Acta 1337: 27\u201339, 1997","journal-title":"Biochimica et Biophysica Acta"},{"key":"389578_CR38","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1524\/ract.1997.79.2.145","volume":"79","author":"RA Boll","year":"1997","unstructured":"Boll RA, Mirzadeh S, Kennel SJ: Optimizations of radiolabeling of immunoproteins with 213Bi. Radiochimica Acta 79: 145\u2013149, 1997","journal-title":"Radiochimica Acta"},{"key":"389578_CR39","first-page":"1158","volume":"24","author":"CH Paik","year":"1983","unstructured":"Paik CH, Ebbert MA, Murphy PR, Lassman CR, Reba RC, Eckelman WC, Pak KY, Powe J, Steplewski K: Factors in-fluencing DTPA conjugation with antibodies by cyclic DTPA anhydride. J Nucl Med 24: 1158\u20131163, 1983","journal-title":"J Nucl Med"},{"key":"389578_CR40","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1255\/ejms.17","volume":"3","author":"KL Bennett","year":"1997","unstructured":"Bennett KL, Sheil MM: Probing the coordination of metal ions by diethylenetriaminepentacetic acid-conjugated proteins with electrospray ionisation mass spectrometry. Eur Mass Spectrum 3: 233\u2013244, 1997","journal-title":"Eur Mass Spectrum"},{"key":"389578_CR41","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1038\/bjc.1998.261","volume":"77","author":"M Ranson","year":"1998","unstructured":"Ranson M, Andronicos N, O'Mullane, Baker MS: Increased plasminogen binding is associated with metastatic breast cancer cells: differential expression of plasminogen binding proteins. Br J Cancer 77: 1586\u20131597, 1998","journal-title":"Br J Cancer"},{"key":"389578_CR42","first-page":"6051","volume":"53","author":"WE Laug","year":"1993","unstructured":"Laug WE, Cao XR, Yu YB, Shimada H, Kruithof EKO: Inhibition of invasion of HT1080 sarcoma cells expressing recombinant plasminogen activator inhibitor 2. Cancer Res 53: 6051\u20136057, 1993","journal-title":"Cancer Res"},{"key":"389578_CR43","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1073\/pnas.92.1.205","volume":"92","author":"BA Mueller","year":"1995","unstructured":"Mueller BA, Yu YB, Laug WE: Overexpression of plasminogen activator inhibitor 2 in human melanoma cells inhibits spontaneous metastasis in scid\/scid mice. Proc Natl Acad Sci USA 92: 205\u2013209, 1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"389578_CR44","first-page":"692","volume":"61","author":"DM Evans","year":"1995","unstructured":"Evans DM, Lin PL: Suppression of pulmonary metastases of rat mammary cancer by recombinant urokinase plasminogen activator inhibitor. Am Surgeon 61: 692\u2013696, 1995","journal-title":"Am Surgeon"},{"key":"389578_CR45","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/1097-0215(20000920)89:5<431::AID-IJC6>3.0.CO;2-V","volume":"89","author":"J-L Yang","year":"2000","unstructured":"Yang J-L, Seetoo D, Wang Y, Ranson M, Berney CR, Ham JM, Russell PJ, Crowe PJ: Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer specific survival, and potential therapeutic targets. Intl J Cancer 89: 431\u2013439, 2000","journal-title":"Intl J Cancer"},{"key":"389578_CR46","first-page":"5829","volume":"52","author":"J Jankun","year":"1992","unstructured":"Jankun J: Antitumour activity of the type 1 plasminogen activator inhibitor and cytotoxic conjugate in vitro. Cancer Res52: 5829\u20135832, 1992","journal-title":"Cancer Res"},{"key":"389578_CR47","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/978-1-4899-1207-7_5","volume-title":"Targeting of Drugs 4.","author":"J Jankun","year":"1994","unstructured":"Jankun J: Targeting of drugs to tumours: the use of the plasminogen activator inhibitor as a ligand. In: Gregoriadis G et al. (eds) Targeting of Drugs 4. Plenum Press, New York, 1994, pp. 67\u201379"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1013850107791.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1023\/A:1013850107791\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1023\/A:1013850107791","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1013850107791.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T04:27:57Z","timestamp":1750480077000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1023\/A:1013850107791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,1]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2002,1]]}},"alternative-id":["389578"],"URL":"https:\/\/doi.org\/10.1023\/a:1013850107791","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"type":"print","value":"0167-6806"},{"type":"electronic","value":"1573-7217"}],"subject":[],"published":{"date-parts":[[2002,1]]}}}